SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

17 June 2025 00:00:00

Adani Ports

1391.70

(-0.62%)

Asian Paints

2264.50

(0.93%)

Axis Bank

1216.70

(0.09%)

Bajaj Finance

922.90

(-1.58%)

Bajaj Finserv

2003.60

(-1.21%)

Bharti Airtel

1855.20

(-0.33%)

Eternal Ltd

247.30

(-1.92%)

HCL Technologi..

1730.15

(0.41%)

HDFC Bank

1929.60

(-0.28%)

Hind. Unilever

2328.85

(0.13%)

ICICI Bank

1423.05

(-0.27%)

IndusInd Bank

809.15

(-1.46%)

Infosys

1640.15

(1.01%)

ITC

417.35

(-0.18%)

Kotak Mah. Ban..

2136.70

(-0.08%)

Larsen & Toubr..

3622.95

(-0.18%)

M & M

3007.80

(-0.43%)

Maruti Suzuki

12595.35

(0.48%)

Nestle India

2361.50

(-1.17%)

NTPC

335.35

(0.48%)

Power Grid Cor..

288.60

(-0.02%)

Reliance Indus..

1431.30

(-0.50%)

St Bk of India

792.20

(-0.08%)

Sun Pharma.Ind..

1648.85

(-2.18%)

Tata Motors

675.00

(-1.70%)

Tata Steel

152.60

(-0.97%)

TCS

3515.25

(0.57%)

Tech Mahindra

1716.60

(1.33%)

Titan Company

3405.35

(-0.96%)

UltraTech Cem.

11383.40

(-0.98%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

SPARC tanks after psoriasis, eczema drug flunks Phase 2 trials	Share Back
(04 Jun 2025)
In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025.
Top